SK Bioscience has laid the groundwork for a return to profitability, slashing its second-quarter operating loss by nearly 58% year-on-year, buoyed by a performance improvement at its German subsidiary IDT Biologika. However, the full first-half picture suggests a full earnings recovery will take more time, as headquarters relocation and rising R&D costs weighed on results.
SK Bioscience disclosed on August 10 that it posted preliminary consolidated second-quarter revenue of 155.7 billion won (approximately $109.8 million) and an operating loss of 15.7 billion won (approximately $11.1 million). Revenue edged down 3.8% from 161.9 billion won a year earlier, but the operating loss narrowed by 21.7 billion won from 37.4 billion won in the same period last year — a 57.9% reduction. The company explained that some in-house vaccine shipments were deferred to the third quarter, temporarily depressing revenue, but confirmed the full volume will be recognized during the current quarter.
Cumulative first-half revenue rose roughly 2.5% to 324.3 billion won (approximately $228.7 million) from 316.4 billion won a year earlier, but the operating loss widened to 60.3 billion won (approximately $42.5 million) from 52.5 billion won. Costs tied to the relocation of the company’s headquarters to Songdo earlier this year and increased R&D spending were the primary drags on first-half performance.
The standout contributor to the narrower second-quarter loss was IDT, the German CDMO subsidiary acquired in 2024. Profitability improved markedly as production volumes increased, driven by key clients, while cost-saving measures — including workforce optimization and yield improvements — began to materialize in earnest. SK Bioscience plans to further streamline IDT’s productivity and cost structure while expanding its global CDMO footprint by securing high-value contracts and new clients across North America, Europe, and Asia.
The company’s overseas vaccine business is also entering an expansion phase. Its influenza vaccine “SkyCellflu” has secured a new supply contract with UNICEF, following earlier deliveries to the Pan American Health Organization (PAHO), and has captured the largest allocation under South Korea’s National Immunization Program (NIP). The varicella vaccine “SkyVaricella” has established a beachhead in the Latin American market through a technology transfer and local production facility agreement with VECOL, Colombia’s state-owned pharmaceutical company.
Next-generation vaccine pipeline development is also accelerating. GBP410, a 21-valent pneumococcal protein conjugate vaccine co-developed with Sanofi, is currently in global Phase 3 clinical trials across the United States and Europe, with the company targeting interim results in the second half of next year. Expansion of commercial production facilities at the Andong L House has also been completed.
Meanwhile, SK Bioscience is strengthening external collaborations to secure new growth engines. It has licensed respiratory syncytial virus (RSV) preventive antibody technology from Gates MRI and is participating in a next-generation Ebola vaccine development program supported by the Coalition for Epidemic Preparedness Innovations (CEPI). The company is also broadening its vaccine portfolio through a next-generation influenza vaccine development project backed by the European Health and Digital Executive Agency (HaDEA) and an injectable rotavirus vaccine licensing agreement with the U.S. Centers for Disease Control and Prevention (CDC).
On the financing front, positive signals have emerged. SK Bioscience was recently selected as a beneficiary of South Korea’s National Growth Fund, securing 300 billion won (approximately $211.5 million) in ultra-low-interest, long-term funding, which will be deployed toward R&D, commercialization preparation, and production facility upgrades.
An SK Bioscience official stated, “In the second half, we intend to expand our global CDMO business centered on IDT while simultaneously advancing proprietary vaccine supply and key pipeline clinical trials, thereby strengthening our mid- to long-term growth foundation.” Whether the narrowing loss trajectory from the second quarter can be sustained through year-end will be a critical inflection point for full-year earnings improvement.